Last reviewed · How we verify

lidocaine infusion

Medical University of Warsaw · FDA-approved active Small molecule

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local anesthesia, Neuropathic pain, Cardiac arrhythmias (ventricular).

At a glance

Generic namelidocaine infusion
Also known asLignocaine, 2% lidocaine hydrochloride, Lidocaine hydrochloride, Preservative Free Lidocaine Hydrochloride, xylocaine iv
SponsorMedical University of Warsaw
Drug classLocal anesthetic / Sodium channel blocker
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain management, Cardiology
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through voltage-gated sodium channels in the neuronal cell membrane. This prevents depolarization and the generation of action potentials, thereby blocking pain signal transmission. When administered as an infusion, it can provide systemic analgesic and anti-inflammatory effects, particularly for neuropathic pain and certain arrhythmias.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: